This document is an excerpt from the EUR-Lex website
Document 52020M9962
Prior notification of a concentration (Case M.9962 — Mylan/Aspen’s EU Thrombosis Business) (Text with EEA relevance) 2020/C 317/08
Prior notification of a concentration (Case M.9962 — Mylan/Aspen’s EU Thrombosis Business) (Text with EEA relevance) 2020/C 317/08
Prior notification of a concentration (Case M.9962 — Mylan/Aspen’s EU Thrombosis Business) (Text with EEA relevance) 2020/C 317/08
PUB/2020/750
OJ C 317, 25.9.2020, p. 24–24
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 25/09/2020; Date of publication
- Author:
- European Commission, Directorate-General for Competition
- Form:
- Announcements
- Additional information:
- EEA relevance
- Legal basis:
-
- 32004R0139 - A04
- Link
- Link
- Link
- Select all documents mentioning this document
- Link
- Related document(s):
-
- 32020M9962 Relation
- 52020M9962(01) Relation
- EUROVOC descriptor:
- Subject matter:
- Directory code:
-
- 08.40.00.00 Competition policy / Concentrations
|
25.9.2020 |
EN |
Official Journal of the European Union |
C 317/24 |
Prior notification of a concentration
(Case M.9962 — Mylan/Aspen’s EU Thrombosis Business)
(Text with EEA relevance)
(2020/C 317/08)
1.
On 17 September 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Mylan Ireland Limited (‘Mylan’, Ireland), |
|
— |
Aspen’s EU Thrombosis Business (the ‘Target’, Mauritius), belonging to the group Aspen Pharmacare Holdings LTD. |
Mylan acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of the Target. The concentration is accomplished by way of purchase of assets.
2.
The business activities of the undertakings concerned are:|
— |
Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and speciality pharmaceuticals in addition to OTC and consumer healthcare products; |
|
— |
The Target comprises certain commercialisation rights and related intellectual property rights of Aspen’s antithrombotic products in the EEA, namely the molecules Nadroparin (brand names Fraxiparine and Fraxodi), Fondaparinux (brand name Arixtra), Certoparin (brand name Mono Embolex) and Danaparoid (brand name Orgaran). |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.9962 — Mylan/Aspen’s EU Thrombosis Business
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
